Prof Andrew Pettitt MA, MB BChir, PhD, MRCP, FRCPath

Professor of Haematology Molecular and Clinical Cancer Medicine

    Biography

    Personal Statement

    I am a Professor of Haematology and an Honorary Consultant Haematologist at the Royal Liverpool University Hospital. I lead a large programme of clinical and translational research focussed on lymphoid malignancy. I have strong links with industry and national collaborative groups in lymphoma and haematological oncology.

    Personal Distinctions

    • Invited to chair a Zevalin advisory board meeting in London (May 2008) (Invitation to Perform, Bayer-Schering 2009)
    • Invited to speak at the French CLL Group meeting, Paris (January 2008) (Invitation to Speak, CCB group 2008)
    • Invited to give a talk on lymphoma to the registrars at Clatterbridge Centre for Oncology (Feb 2008) (Invitation to Speak, CCO 2008)
    • Invited to speak at Celgene meeting in Manchester (May 2008) (Invitation to Speak, Celgene 2008)
    • Invited to speak at the CTCL Supranetworks meeting, Liverpool (May 2008) (Invitation to Speak, Cephalon 2008)
    • Invited to speak at Schering/NWHA meeting, Haydock (February 2008) (Invitation to Speak, Schering/NWHA 2008)
    • Invited to speak at the CTCL round table meeting, Manchester (May 2008) (Invitation to Speak, CTCL 2008)
    • Invited to present on CLL at the ACC meeting, Maritime Museum (March 2008) (Invitation to Speak, ACC 2008)
    • Invited to speak at the Lancashire and S. Cumbria Haem NSSG (June 2008) (Invitation to Speak, Lancs and S Cumbria Haem NSSG 2008)
    • Invited to speak at EHA, Copenhagen (June 2008) (Invitation to Speak, EHA 2008)
    • Invited to speak at the annual meeting of the French CLL Co-operative Group (November 2007, Paris) (Invitation to Speak, French CLL Co-operative Group 2007)
    • Invited to contribute to the Department of Health Cancer Reform Strategy Document (April 2007) (Invitation to Perform, Department of Health 2007)
    • Invited to contribute to the NICE appraisal of rituximab in follicular lymphoma (June 2007) (National Institute for Clinical Excellence 2007)
    • Invited to speak at the North West Haematology Association (Feb 2007, Knutsford) (Invitation to Speak, NWHA 2007)
    • Invited member of national advisory board for rituximab (April 2007) (Roche 2007)
    • Invited to chair a session on CLL and lymphoma at the annual BSH meeting (Bournemouth, April 2007) (British Sociey for Haematology 2007)
    • Invited to chair a national advisory board on Campath in CLL (June 2007) (Invitation to Speak, Schering Healthcare Ltd 2007)
    • Invited speaker at the sixth annual meeting of the German CLL Study Group (October 2006, Cologne) (Invitation to Speak, GCLLSG & Schering Healthcare Ltd 2006)
    • Elected Chairman of the UK CLL Forum (November 2006) (UK CLL Forum 2006)
    • Invited presentation at a stand-alone meeting on CLL and lymphoma (April 2006, Athens ) (Invitation to Speak, Schering Healthcare Ltd 2006)
    • Invited presentation at the Blood Products Working Party of the EMEA (July 2006, London) (Invitation to Speak, EMEA 2006)
    • Invited member of international advisory board for alemtuzumab (New York, Sep 2006) (Schering 2006)
    • Invited member of regional advisory board for rituximab (Chester, Oct 2006) (Roche 2006)
    • Invited speaker at MRCPath regional educational meeting (Liverpool, Sep 2006) (Invitation to Speak, Royal College of Pathologists 2006)
    • Invited to represent the BCSH at the NICE appraisal of fludarabine in CLL (London, Sep 2006) (Invitation to Speak, British Committee for Standards in Haematology 2006)
    • Invited member of rasburicase advisory panel (Feb 2006) (Sanofi 2006)
    • Invited member of national fludarabine advisory panel (London, Feb 2006) (Schering Healthcare Ltd 2006)
    • Invited to speak at a departmental seminar (November 2006, Edinburgh) (Invitation to Speak, Schering Healthcare Ltd 2006)
    • Invited to speak at a research seminar (May 2002, Birmingham) (Bhm 2006)
    • Invited to speak at a reseach seminar (September 2006, Royal Free Hospital) (Invitation to Speak, Royal Free Hospital 2006)
    • Invitation to speak at a regional meeting on CLL (June 2006, Warrington) (Invitation to Speak, Schering Healthcare Ltd 2006)
    • Invited to be member of the national steering group on fludarabine in CLL (February 2006, London) (Schering Healthcare Ltd 2006)
    • Invited to speak at the annual meeting of the British Society of Haematology (April 2006, Edinburgh) (Invitation to Speak, British Society of Haematology 2006)
    • Invited to speak at the inaugural annual meeting of the Leukaemia Care charity (April 2006, London) (Invitation to Speak, Leukemia Care 2006)
    • Invited to speak at the annual LRF grant-holder's meeting (November 2005, London) (Invitation to Speak, Leukaemia Research Fund 2005)
    • Invited to speak at a regional meeting on CLL (January 2005, Manchester) (Invitation to Speak, N/K 2005)
    • Invited to deliver the keynote lecture at the annual lymphoma trials meeting (November 2005, London) (Keynote Speech, Prof David Linch, UCLH 2005)
    • Invited to speak at the annual general meeting of the UK CLL Forum (November 2005, London) (Invitation to Speak, Prof TJ Hamblin, Chairman of UK CLL Forum 2005)
    • Invitation to Chair a Regional Meeting on CLL and lymphoma (July 2003, Prestatyn) (Invitation to Speak, N/K 2005)
    • Invited to speak at a Royal Marsden Hospital educational meeting (September 2005, London) (Invitation to Speak, Royal Marsden Hospital 2005)
    • Invited to speak at the the British Society for Haematology annual meeting (April 2005, Manchester) (Invitation to Speak, British Society of Haematology 2005)
    • Invited to speak at the regional launch meeting of Zevalin (May 2004, Liverpool) (Invitation to Speak, N/K 2004)
    • Invitated to speak at the South West Haematologists Association (March 2004, Taunton) (Invitation to Speak, N/K 2004)
    • Invited to organise the annual scientific meeting of the UK CLL Forum (May 2004, London) (UK CLL Forum 2004)
    • Invited to speak at the UK Key Advances Masterclass in CLL (June 2004, London) (Invitation to Speak, N/K 2004)
    • Invitated to chair a regional meeting on skin lymphoma (November 2004, Liverpool) (N/A 2004)
    • Invited to speak at the UK Key Advances meeting on CLL (September 2003, London) (Invitation to Speak, N/K 2003)
    • Invited to chair a session at the American Society of Hematology (December 2003, San Diego) (Invitation to Speak, American Society of Hematology 2003)
    • Invited to speak at a regional meeting on CLL (January 2003, Manchester) (Invitation to Speak, N/K 2003)
    • Invited to speak at a meeting of the Lymphoma Association charity (April 2003, Chester) (N/K 2003)
    • Invited to speak at a regional meeting on CLL (April 2003, Leeds) (Invitation to Speak, N/K 2003)
    • Invited to take part in a National round-table discussion on the management of CLL (N/K 2003)
    • Invited to speak at a research seminar (January 2002, Nottingham) (Nttm 2002)
    • Invited to speak at the scienfitic meeting of UK CLL Forum (April 2001, London) (Invitation to Speak, UK CLL Forum 2001)
    • Invitation to speak at a research seminar (May 2001, Leeds) (Invitation to Speak, Leeds 2001)
    • Invited to speak at a research seminar (June 2000, Birmingham) (Bhm 2000)

    Administrative Roles

    • My two main leadership roles at present are being Head of the University of Liverpool Department of Molecular and Clinical Cancer Medicine (from 2011) and Chair of the National Cancer Research Institute (NCRI) Haematological Oncology Clinical Studies Group (from 2012). I was previously Chair of the UK CLL Forum (2006-2012) and a member of the Cancer Research UK Clinical Trials and Awards Committee (CTAAC) (2009-2012). I represent the University on the Clatterbridge Cancer Centre NHS Foundation Trust Council of Governors and sit on a numebr of other local and national committees.

    Untitled Document